Author | Martin J. van den Bent, MD | OncLive

Author | Martin J. van den Bent, MD

Articles

Dr. van den Bent on Temozolomide and Depatux-M in Glioblastoma

September 25, 2018

Video

Martin J. van den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, the Netherlands, discusses the combination of temozolomide (Temodal) and depatuxizumab mafodotin (depatux-m) in the treatment of patients with glioblastoma.

Dr. van den Bent on INTELLANCE 2 Trial for Recurrent Glioblastoma

August 01, 2018

Video

Martin J. van den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, the Netherlands, discusses the INTELLANCE 2 trial for recurrent glioblastoma.

Dr. van den Bent on Adjuvant Temozolomide in Anaplastic Glioma

July 27, 2016

Video

Martin J. Van Den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, the Netherland, discusses the results of an interim analysis of the randomized phase III CANTON trial, which investigated concurrent and adjuvant temozolomide in patients with anaplastic glioma without a 1p/19q co-deletion.

Dr. van den Bent Discusses Bevacizumab Plus Lomustine in Recurrent Glioblastoma

November 15, 2014

Video

Martin J. van den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands, discusses the BELOB trial, which examined bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma.

x